Terkko Navigator / Wennerberg, K(rister)* (FIMM)

Therapeutic targeting of KSP in preclinical models of high-risk neuroblastoma.

Immunogenomic Landscape of Hematological Malignancies.

KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia.

Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition.

Immunogenomic Landscape of Hematological Malignancies.

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer.

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.

Prediction of drug combination effects with a minimal set of experiments.

Identification of novel regulators of STAT3 activity.

Improved detection of differentially represented DNA barcodes for high-throughput clonal phenomics.

Breeze: an integrated quality control and data analysis application for high-throughput drug screening.

Phosphoproteome and drug response effects mediated by the three Protein Phosphatase 2A inhibitor proteins CIP2A, SET and PME-1.

Exploration of databases and methods supporting drug repurposing: a comprehensive survey.

A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening.

Human Tumor-Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing.

Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.

Drug screening approach combines epigenetic sensitization with immunochemotherapy in cancer.

Novel Screening Method Identifies PI3Kα, mTOR, and IGF1R as Key Kinases Regulating Cardiomyocyte Survival.

ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.

Chemogenomic Analysis of the Druggable Kinome and Its Application to Repositioning and Lead Identification Studies.

Multi-parametric single cell evaluation defines distinct drug responses in healthy hematological cells that are retained in corresponding malignant cell types.

Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify Kras Mutant Lung Cancers.

Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer.

Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma.

Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets.

8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.

Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.

Interactive visual analysis of drug-target interaction networks using Drug Target Profiler, with applications to precision medicine and drug repurposing.

Anagrelide for gastrointestinal stromal tumor.

Integrated Analysis of Drug Sensitivity and Selectivity to Predict Synergistic Drug Combinations and Target Coaddictions in Cancer.

KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism.

Drug Target Commons 2.0: a community platform for systematic analysis of drug-target interaction profiles.

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.

Drug sensitivity screening and genomic characterization of 45 HPV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy.

Toward universal protein post-translational modification detection in high throughput format.

Patient-customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients.

Methods for High-throughput Drug Combination Screening and Synergy Scoring.

Genomic Perturbations Reveal Distinct Regulatory Networks in Intrahepatic Cholangiocarcinoma.

Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions.

Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling.

Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.

A Community Challenge for Inferring Genetic Predictors of Gene Essentialities through Analysis of a Functional Screen of Cancer Cell Lines.

Systematic identification of feature combinations for predicting drug response with Bayesian multi-view multi-task linear regression.

Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.

Computational-experimental approach to drug-target interaction mapping: A case study on kinase inhibitors.

A transcriptomics data-driven gene space accurately predicts liver cytopathology and drug-induced liver injury.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Seed-effect modeling improves the consistency of genome-wide loss-of-function screens and identifies synthetic lethal vulnerabilities in cancer cells.

High-Throughput Dual Screening method for Ras Activities and Inhibitors.